As per the estimates from CDC's (Centers for Disease Control and Prevention) Autism and Developmental Disabilities Monitoring (ADDM) Network, around 1 in 36 children were reported to be identified with autism spectrum disorder. With the growing number of cases, there is a heightened focus on expediting the development of promising autism drugs and accelerating clinical trials. Moreover, rising public awareness and advocacy from autism organizations are also fuelling the demand for advanced treatment options.
The Autism Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into autism therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Autism. The autism report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The autism pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with autism treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to autism.
Autism or autism spectrum disorder (ASD) refers to a neurological and developmental disorder characterized by deficits in social communication and social interaction. Autistic individuals typically show inflexible, repetitive, and restricted patterns of interests, behaviors, and activities. Some people with autism can live independently whereas certain individuals may require life-long support and care.
Behavioral therapy is a widely used approach to improve social, communication, and learning skills in autistic people. For irritability and aggression, autism therapeutics include FDA-approved risperidone and aripiprazole for managing severe behavioral symptoms. Pharmaceutical companies are actively developing novel drug candidates such as gene and RNA-based therapies, cannabidiol (CBD), and oxytocin therapies. Additionally, the adoption of innovative technologies in drug development, along with adherence to autism treatment guidelines, is expected to improve patient outcomes and aid pipeline expansion in the near future.
According to the World Health Organisation (WHO), approximately 1 in 100 children are affected by autism, with the prevalence of the condition unknown in many low- and middle-income countries. On the other hand, the CDC's Autism and Developmental Disabilities Monitoring (ADDM) Network estimates that 1 in 36 children has been identified with autism.
Autism spectrum disorder is roughly 4 times more common in boys than in girls. It is reported to occur in all ethnic, racial, and socioeconomic groups.
This section of the report covers the analysis of autism drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of autism emerging drugs undergoing clinical development.
The drug molecule categories covered under autism pipeline analysis include small molecules, biologics, peptides, gene and RNA-based therapies, and natural compounds and cannabinoids. The autism report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for autism.
The EMR report for the autism drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed autism therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in autism clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Astrogen, Inc., the objective of this randomized, double-blinded, multicenter clinical trial is to investigate the efficacy and safety of AST-001 in children with autism spectrum disorder. The study is under Phase III clinical development and has an estimated 160 participants.
Curemark is conducting a Phase III open-label extension study aimed at examining the efficacy and safety of autism drug candidate CM-AT in treating autism with all levels of fecal chymotrypsin. The interventional study has enrolled about 405 children and is expected to be completed by January 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Autism Drug Report provides a strategic overview of the latest and future landscape of treatments for autism. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within autism pipeline insights.
Autism Spectrum Disorders Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share